Logo

Roche Report Results of Evrysdi (risdiplam) in FIREFISH Study for Infants with Type 1 SMA

Share this

Roche Report Results of Evrysdi (risdiplam) in FIREFISH Study for Infants with Type 1 SMA

Shots:

  • Roche has reported the data from the dose-finding Part 1 of the FIREFISH study assessing Evrysdi in patients aged 1-7mos. with Type 1 SMA. Part 1 evaluated several doses of Evrysdi and determined the therapeutic dose of 0.2 mg/kg for Part 2
  • Part 1 data demonstrated that 99% of infants survive without permanent ventilation @12 mos. & 33% sit without support for at least 5sec. In an exploratory analysis- 41% received high dose- 53% achieved upright head control- and 6% were able to stand as assessed by the HINE-2.- 86% were able to feed orally
  • The researcher also assessed motor function with CHOP-INTEND & demonstrated that 52% achieved a CHOP-INTEND score of ≥40 points

 ­ Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions